| Website | covagen.com |
| Category | BioTech |
| Phone | 41(0)44 635 60 33 |
| Employees | |
| Founded | 1/07 |
| Description | Protein Therapeutics |
| Total | $40.5M |
| Seed, 10/09 MP Healthcare Venture Management Novartis Venture Fund | |
| Series A, 12/09 Ventech | $34.2M |
| Series A, 11/10 Seroba Kernel Edmond de Rothschild Venture Capital MP Healthcare Venture Management Novartis Venture Funds Ventech | $6.3M |
Covagen AG develops protein-based therapeutics for the treatment of inflammatory diseases and cancer. Its products enable the isolation of high affinity protein-based binders called Fynomers, which changes the activity of target molecules relevant in various diseases. Covagen AG was founded in 2007 and is based in Zürich, Switzerland.
